Literature DB >> 20549562

Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation.

Kai-Hsi Hsu1, Hung-Wen Tsai, Pin-Wen Lin, Yun-Shang Hsu, Yan-Shen Shan, Pei-Jung Lu.   

Abstract

BACKGROUND: Osteopontin (OPN) is a multifunctional secreted glycophosphoprotein involved in miscellaneous physiologic and pathologic processes and is functionally related to the transmembrane receptor CD44. Although OPN expression has been identified to be associated with poor prognosis in several gastrointestinal malignancies, its expression in gastrointestinal stromal tumor (GIST) has not been thoroughly investigated. This study was designed to evaluate the clinicopathologic significance of OPN expression in patients with resectable GIST.
METHODS: OPN expression was analyzed for its clinicopathologic significance in surgical specimens from 99 patients with resectable GIST by immunohistochemistry. In situ Proximity Ligation Assay was used for examining OPN and CD44 interaction in tumor tissues and GIST cell lines. The in vitro effects of OPN and its interaction with CD44 also were assessed.
RESULTS: Increased OPN expression was a significant poor prognostic factor that independently predicted recurrence and poor disease-free survival in patients with resectable GIST. The interaction of OPN and CD44 was confirmed by their significant correlation in both GIST tumor tissues and cell lines by in situ Proximity Ligation Assay analysis. OPN and its interaction with CD44 were related to increased mitosis and significantly enhanced GIST tumor cell proliferation in vitro.
CONCLUSIONS: Our study identified the clinicopathologic significance and biologic effects of OPN expression in resectable GIST. Increased OPN expression was an independent poor prognostic factor and its interaction with CD44 significantly correlated with increased mitosis as well as in vitro proliferation-promoting effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549562     DOI: 10.1245/s10434-010-1143-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

Review 1.  Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis.

Authors:  Bin Peng; Yi-Han Wang; Zhuo Huang; Shi-Jian Feng; Yong-Sheng Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Effects of CD44 and E-cadherin overexpression on the proliferation, adhesion and invasion of ovarian cancer cells.

Authors:  Meiya Mao; Xiaojiao Zheng; Bohong Jin; Fubin Zhang; Linyan Zhu; Lining Cui
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

Review 3.  Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes.

Authors:  Marta Magdalena Fudalej; Anna Maria Badowska-Kozakiewicz
Journal:  Oncol Lett       Date:  2021-03-28       Impact factor: 2.967

4.  Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry.

Authors:  Jing Li; Guang-Zhi Yang; Zi-Man Zhu; Zhi-Yong Zhou; Lin Li
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

5.  Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin.

Authors:  Xiang-Qian Zhao; Jia-Hong Dong; Wen-Zhi Zhang; Zhe Liu
Journal:  Diagn Pathol       Date:  2011-10-13       Impact factor: 2.644

Review 6.  The Effect of Osteopontin on Microglia.

Authors:  Huan Yu; Xiaohong Liu; Yisheng Zhong
Journal:  Biomed Res Int       Date:  2017-06-18       Impact factor: 3.411

7.  Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors.

Authors:  Kai-Hsi Hsu; Hung-Wen Tsai; Pin-Wen Lin; Yun-Shang Hsu; Pei-Jung Lu; Yan-Shen Shan
Journal:  World J Surg Oncol       Date:  2014-06-20       Impact factor: 2.754

Review 8.  Osteopontin b and c Splice isoforms in Leukemias and Solidzzm321990Tumors: Angiogenesis Alongside Chemoresistance

Authors:  Akram Mirzaei; Saeed Mohammadi; Seyed H Ghaffari; Marjan Yaghmaie; Mohammad Vaezi; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.